Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants ...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) on January 6 and set a price target of $181.00. The company’s shares closed ...
It’s called JnJ Bakery Cafe, and you’ll find it on Barrette Street where the much-loved taco place Ola Cocina Taqueria had been for quite a few years. In the weeks before the holidays ...
Johnson & Johnson (JNJ) shares rallied to their highest level this year after reporting a combination of its lung cancer drugs, Rybrevant and Lazcluse, kept people alive for longer when suffering ...
Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody ...
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
Fia Jenika (35), peserta BPJS Kesehatan Bengkulu yang merasakan banyak manfaat dengan terdaftar sebagai peserta JKN. TRIBUNENWS.COM, JAMBI - Pemerintah Indonesia meluncurkan Program Jaminan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback